A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety and Pharmacokinetics of Single Doses of GT300 in Healthy Subjects
Latest Information Update: 05 Jun 2023
At a glance
- Drugs GT 300 (Primary)
- Indications Lewy body disease
- Focus Pharmacokinetics
- Sponsors Generian Pharmaceuticals
- 22 Jul 2021 New trial record